Document:

QuickLinks
 -- Click here to rapidly navigate through this document

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

 
 

Exhibit 10.29    
    

Veridex,
LLC

1001 US Route 202

Raritan, NJ 08869-0606 

November
10, 2003 

Ed
Erickson,

Chairman and CEO

Immunicon Corporation

3401 Masons Mill Road, Suite 100

Huntingdon Valley, PA 19006-3574 

Subject:
Development, License and Supply Agreement between Immunicon Corporation and Ortho-Clinical Diagnostics, Inc. dated August 17, 2000. 

Dear
Ed: 

        As
you know, all of the business of Advanced Diagnostic Systems is now conducted by Veridex, LLC, and Veridex, LLC assumes all the rights, interests, and obligations under the subject
Agreement. Veridex LLC represents that it is an "Affiliate" of Ortho-Clinical Diagnostics, Inc., and not a "Third Party" as those terms are defined in the subject Agreement, and that Veridex,
LLC has the full right
and power to assume all the rights, interests and obligations of Ortho-Clinical Diagnostics, Inc. under the subject Agreement without the prior written consent of Immunicon Corporation,
pursuant to section 16.3.1(a)(i) of the subject Agreement. 

        We
propose modifying the subject Agreement by nullifying all milestones described in section 5 that have not yet been fully performed (except for the milestone enumerated in
section 5.2.6, as clarified in the attached table (new Exhibit X), which milestone shall remain executory). However, the parties have jointly reviewed the project and have determined
that the CellTracks technology will not be available at a time sufficient to meet the portion of the milestone described in section 5.2.6 that refers to such technology. Accordingly, the last
sentence of such milestone shall be stricken from the Agreement and the adjustment described beneath the attached table shall be made. The following milestone provisions shall also be added in place
of those which have been nullified. Where the same event appears in more than one milestone, it establishes the order or timing in which events are to occur and does not require repetition of that
event. Additionally, a new section 3.5.1 is provided to completely replace that section as currently drafted in the Agreement and a new Exhibit Y is provided. All other terms and
conditions of the Agreement shall remain the same. Please indicate your acceptance by signing in the appropriate space below. 

        3.5.1    Immunicon
shall allocate a budget covering all Clinical Trial Expenses for Cellular Analysis Products for all monitoring, adjuvant, recurrence, companion biopsy, and
all other non-screening indications described or referred to in this Agreement, and shall bear up to Five Million dollars (US$5,000,000) for Clinical Trial Expenses for the first Cellular
Analysis Product for screening the general population for a major cancer as may be agreed to by the Steering Committee and provided, upon review of the data produced in such Clinical Trial, the
Steering Committee continues to approve such Clinical Trial. If such screening Clinical Trial Expenses exceed Five Million dollars (US$5,000,000) then Immunicon shall not be obligated to pay any such
excess amount and OCD shall pay up to Five Million dollars (US$5,000,000) of such additional screening Clinical Trial Expenses. If such additional screening Clinical Trial Expenses exceed Five Million
Dollars ($5,000,000), then the parties shall negotiate in good faith the future terms and conditions under which Clinical Trial for Cellular Analysis Products for such screening will be funded. OCD
shall also pay the reasonable incremental Clinical Trial Expenses attributable to indications in support of OCD products or methods for diagnostic testing 

or
testing for determinations regarding therapy based on [**]. Immunicon shall keep accurate records of the incremental Clinical Trial Expenses to be borne by OCD under this
Section 3.5.1 and shall provide OCD with an itemized list and description of such expenses in sufficient detail for OCD to assess their validity. Immunicon shall provide OCD with such a list
within 90 days of the accrual of such expenses. OCD shall pay to Immunicon such reasonable incremental Clinical Trial Expenses within 60 days of receipt of such list. The list provided
by Immunicon under this Section 3.5.1 shall be subject to the Audit Rights set forth in Section 3.6.3. 

        5.2.10    Metastatic
Colorectal or Prostate Cancer Therapy Monitoring. 

        5.2.10.1    Five
Hundred Thousand Dollars (US$500,000) upon initiation of a Clinical Trial for a Cellular Analysis Product in support of metastatic colorectal or prostate
Cancer therapy monitoring, and prediction/prognostic claims. This milestone shall be complete when all of the following activities have been completed: (a) the Steering Committee selects the
Cancer to which this milestone shall be directed (i.e., either colorectal or prostate) (b) approval by the Steering Committee of a Clinical Trial protocol, (c) delivery of the protocol
to the FDA for comment, (d) Principal Investigator and Institutional Review Board approval has been obtained in three (3) clinical sites for conducting the Clinical Trial,
(e) clinical sites have been trained, are under contract, and materials have been delivered, and (f) the first patient has been enrolled in such a Clinical Trial. The completion date for
this milestone is June 30, 2004. 

        5.2.10.2    Five
Hundred Thousand Dollars (US$500,000) upon the transfer to OCD of a draft appropriate regulatory submission for the FDA of a Cellular Analysis Product that
includes a therapy monitoring claim for metastatic colorectal or prostate Cancer. This milestone shall be complete when all of the following activities have been completed: (a) OCD is in
receipt of such a draft submission incorporating data and information that is pertinent to Immunicon's responsibilities under this Agreement, and (b) the Steering Committee has approved such
submission as properly prepared for transfer to the FDA. The completion date for this milestone is November 30, 2005. 

        5.2.11    Prostate
Cancer: [**] 

        5.2.11.1    Three
Hundred Thousand Dollars (US$300,000) upon the successful demonstration by Immunicon that a Cellular Analysis Product is suitable, in combination with either
a method or assay [**]. This milestone shall be complete when all of the following activities have been completed: (a) provide OCD with a complete report of research
results relating to the use of Cellular Analysis Products on [**], (b) obtain the acceptance of the Steering Committee for a proposed method for Large Volume sample
processing to enable [**] of whole blood to be used on the automated sample preparation system (the current version of which is referred to as the AutoPrep device) with a
single tube for clinical investigations, (c) demonstrate a method to be used on such automated sample preparation system capable of preparing a clinical sample for use in this application from
[**] of whole blood [**], (d) [**], (e) [**], (f) propose
[**] compatible with the automated sample preparation system sample tube that can be processed on such system and analyzed on the Automated Cell Analysis System (the current
version of which is referred to as the CellTracks instrument), and (g) summarize results from these experiments to the Steering Committee and determine (along with the involvement of OCD) the
best approach for developing a process likely to obtain Regulatory Approval for [**]; wherein, in each of the foregoing requirements, data shall have been obtained according to
protocols set form in Exhibit Y as such exhibit shall be modified from time to time by the parties. The completion date for this milestone is September 30, 2004. 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

        5.2.11.2.    Three
Hundred Thirty Three Thousand Dollars (US$333,000) upon the initiation of a Clinical Trial for evaluating the use of a Cellular Analysis Product produced by
Immunicon in combination with a method or assay [**]. This milestone shall be complete when all of the following activities have been completed: (a) conduct a Clinical
Trial readiness review and obtain Steering Committee approval of a Clinical Trial protocol for this application that includes cell capture with the use of Immunicon Cellular Analysis Products
[**], (b) delivery of the protocol to the FDA for comments, (c) Principal Investigator and Institutional Review Board approval has been obtained in
[**] clinical sites for conducting the Clinical Trial, (d) clinical sites have been trained, are under contract, and materials have been delivered, and (e) the
first patient has been enrolled in such a Clinical Trial. The completion date for this milestone is June 30, 2005. 

        5.2.11.3    Five
Hundred Thousand Dollars (US$500,000) upon transfer to OCD of a properly prepared appropriate regulatory submission for FDA approval for a Cellular Analysis
Product that includes a claim for the use of a Cellular Analysis Product produced by Immunicon by itself or in combination with a method or assay [**]. This milestone shall be
complete when all of the following activities have been completed: (a) OCD is in receipt of such a submission incorporating data and information that is pertinent to Immunicon's
responsibilities under this Agreement, and (b) the Steering Committee has approved such submission as properly prepared for transfer to the FDA. The completion date for this milestone is
December 31, 2007. 

        5.2.12    Lung
Cancer Adjuvant Prognosis and Recurrence Monitoring. 

        5.2.12.1    Three
Hundred Thirty Three Thousand Dollars (US$333,000) upon initiation of a Clinical Trial for a Cellular Analysis Product in support a non-small cell
lung Cancer prognostic claim in the adjuvant setting and a non-small cell lung Cancer recurrence monitoring claim. This milestone shall be complete when all of the following activities
have been completed: (a) approval by the Steering Committee of a Clinical Trial protocol which includes cell enumeration and cell capture with the use of Immunicon Cellular Analysis Products
and [**] (b) delivery of the protocol to the FDA for comments, (c) Principal Investigator and Institutional Review Board approval has been obtained in
[**] clinical sites for conducting the Clinical Trial, (d) clinical sites have been trained, are under contract, and the materials have been delivered to them, and
(e) the first patient had been enrolled in such a Clinical Trial that uses the
Automated Cell Analysis System and associated sample preparation instrumentation (the current versions of which are referred to as CellTracks and AutoPrep instruments, respectively). The completion
date for this milestone is October 31, 2004. 

        5.2.12.2    Two
Hundred Fifty Thousand Dollars (US$250,000) upon the completion of an interim patient accrual review for a fully accrued Clinical Trial for a Cellular Analysis
Product in support of a non-small cell lung Cancer prognostic claim in the adjuvant setting and a non-small cell lung Cancer recurrence monitoring claim. This milestone shall
be complete when all of the following activities have been completed: (a) at least [**] of the target number of subjects (as determined by the Steering Committee) have
been enrolled in the Clinical Trial according to the protocol referred to above and meet inclusion/exclusion criteria, and upon the completion of this activity, (b) a progress review with all
relevant reportable results, including demographics, and updated timeline has been presented to the Steering Committee and approval has been obtained, (c) all relevant background data necessary
to support the Clinical Trial concerning the subjects has been obtained, summarized, presented to, and accepted by the Steering Committee. The completion date for this milestone is March 31,
2006. 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

        5.2.12.3    Five
Hundred Thousand Dollars (US$500,000) upon the transfer to OCD of a properly prepared appropriate regulatory submission for a Cellular Analysis Product in
support of a non-small cell lung Cancer prognostic claim in the adjuvant setting. This milestone shall be complete when all of the following activities have been completed: (a) OCD
is in receipt of such a submission for each of the claims incorporating data and information that is pertinent to Immunicon's responsibilities under this Agreement and (b) the Steering
Committee has approved such submission as properly prepared for transfer to the FDA. The completion date for this milestone is December 31, 2007. 

        5.2.13    Colorectal
or Breast Cancer Adjuvant Prognosis and Recurrence Monitoring. 

        5.2.13.1    Three
Hundred Thirty Three Thousand Dollars (US$333,000) upon initiation of a Clinical Trial for a Cellular Analysis Product with a colorectal or breast Cancer
prognostic claim in the adjuvant
setting and a colorectal or breast Cancer recurrence monitoring claim. This milestone shall be complete when all of the following activities have been completed: (a) the Steering Committee
selects the Cancer to which this milestone shall be directed (i.e., either colorectal or breast) (b) approval by the Steering Committee of a Clinical Trial protocol which includes cell
enumeration and cell capture with the use of Immunicon Cellular Analysis Products and [**] (c) delivery of the protocol to the FDA for comments, (d) Principal
Investigator and Institutional Review Board approval has been obtained in [**] clinical sites for conducting the Clinical Trial, (e) clinical sites have been trained,
are under contract, and, the materials have been delivered to them, and (f) the first patient has been enrolled in a Clinical Trial that uses the Automated Cell Analysis System and associated
sample preparation instrumentation (the current versions of which are referred to as CellTracks and AutoPrep instruments, respectively). The completion date for this milestone is January 31,
2005. 

        5.2.13.2    Two
Hundred Fifty Thousand Dollars (US$250,000) upon the completion of an interim patient accrual review of a fully accrued Clinical Trial for a Cellular Analysis
Product with a colorectal or breast Cancer prognostic claim in the adjuvant setting and a colorectal or breast Cancer recurrence monitoring claim. This milestone shall be complete when all of the
following activities have been completed: (a) at least [**] of the target number of subjects (as determined by the Steering Committee) have been enrolled in the Clinical
Trial and meet the inclusion/exclusion criteria as set forth in the protocol referred to above, and upon completion of this activity, (b) a progress review with all relevant reportable results,
including demographics, and updated timeline has been presented to the Steering Committee and approval has been obtained and (c) all relevant background data necessary to support the Clinical
Trial concerning the subjects has been obtained, summarized, presented to, and accepted by the Steering Committee. The completion date for this milestone is June 30, 2006. 

        5.2.13.3    Five
Hundred Thousand Dollars (US$500,000) upon the transfer of OCD of a properly prepared appropriate regulatory submission for a Cellular Analysis Product in
support of a colorectal or breast Cancer prognostic claim in the adjuvant setting. This milestone shall be complete when all of the following activities have been completed: (a) OCD is in
receipt of such a submission for each of the claims incorporating data and information that is pertinent to Immunicon's responsibilities under this Agreement and (b) the Steering Committee has
approved such submission as properly prepared for transfer to the FDA. The completion date for this milestone is December 31, 2007. 

        5.2.14    Tumor
Cell Profiling with Analyte Specific Reagents. Two Hundred Thousand Dollars (US$200,000) upon the development of assay components comprising antibodies, and
similar substances formulated as reagents which, through the use of Immunicon Technology, can be used in a diagnostic application for identification and characterization of Cancer cells (tumor cell
profiling reagents). This milestone shall be complete when all of the following activities have been completed: (a) the Steering Committee has approved a formal Product Development Process by
which such reagents will be developed, (b) such reagents for the detection of [**] have been fully developed and 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

the
first commercially saleable lot of such reagent has been produced by [**], or [**] months after Immunicon receives a forecast from OCD,
whichever occurs later (c) such reagents for the detection of the [**] have been initially developed and have successfully completed a Production Readiness Review by
[**], according to the process set forth in 5.2.14(a) above, and (c) commercial rights for suitable antibodies to be used commercially for detecting
[**] have been obtained and the commercial suitability of their use has been demonstrated and approved by the Steering Committee. The completion date for this milestone is
September 30, 2004. 

        5.2.15.    Large
Volume Sample Processing. Five Hundred Thousand Dollars (US$500,000) upon the complete development and Regulatory Approval by FDA of a commercially viable
method for processing large volume samples of whole blood in Immunicon Automated Cell Analysis Systems. This milestone shall be complete when all of the following activities have been completed:
(a) the Steering Committee has approved a regulatory and clinical strategy regarding such method (b) such a device and method for processing at least [**] of
whole blood has been developed and the clinical and regulatory strategy has been implemented, (c) appropriate Regulatory Approval of the process is obtained, and (d) Immunicon Automated
Cell Analysis Systems are available for commercial use and are capable of performing such method without a need for further modification. The completion date for this milestone is July 31,
2006. 

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

 
 

Exhibit X: Revised Milestone Table(6)    
    

	MS

#
	 	Agmt

Section
	 	Title
	 	SubTitle
	 	Target

Date
	 	Adjustment
	 	Successful Completion

Criteria
	 	Sample

Process
	 	Detection
	 	Note
	 	Amount

($US)

	6	 	5.2.6	 	Commercial Readiness for Breast Cancer Therapy Monitoring	 	 	 	1Q03	 	See Note 2a	 	Steering Committee approves product release for sale of a FDA-approved breast cancer therapy monitoring system and completion of other criteria set forth in 5.2.6	 	AutoPrep	 	CellTracks	 	1	 	1,500,000 See Note 2
	

7a	
 	

5.2.10.1	
 	

Metastatic Colorectal or Prostate Cancer Monitoring: (with prognostic and prediction claims)	
 	

Initiate Clinical Study	
 	

9/30/03	
 	

6/30/04	
 	

Protocol approved by OCD and IC and sent to FDA, clinical sites ready, and first patient enrolled	
 	

AutoPrep	
 	

CellTracks	
 	

3	
 	

500,000
	

7b	
 	

5.2.10.2	
 	

"	
 	

Deliver Draft Regulatory Submission to OCD	
 	

2/28/05	
 	

11/30/05	
 	

Steering Committee approves regulatory submission	
 	

AutoPrep	
 	

CellTracks	
 	

 	
 	

500,000
	

8a	
 	

5.2.11.1	
 	

Prostate Cancer: [**]	
 	

Feasibility Complete	
 	

12/31/03	
 	

9/30/04	
 	

Demonstrate feasibility of Large Blood Volume Method [**], and propose product concept	
 	

AutoPrep	
 	

CellTracks	
 	

4: Exhibit Y	
 	

300,000
	

8b	
 	

5.2.11.2	
 	

"	
 	

Initiate Clinical Study	
 	

9/30/04	
 	

6/30/05	
 	

Steering Committee approves Trial readiness, protocol sent to FDA, sites ready, and first patient enrolled	
 	

AutoPrep	
 	

CellTracks	
 	

3

5	
 	

333,000
	

8c	
 	

5.2.11.3	
 	

"	
 	

Deliver Regulatory Submission to OCD	
 	

12/31/06	
 	

12/31/07	
 	

Steering Committee approves regulatory submission for adjuvant prognosis	
 	

AutoPrep	
 	

CellTracks	
 	

 	
 	

500,000
	

9a	
 	

5.2.12.1	
 	

Lung Cancer: Adjuvant Prognosis and Recurrence Monitoring	
 	

Initiate Clinical Study	
 	

1/31/04	
 	

10/31/04	
 	

Steering Committee approves readiness, protocol sent to FDA, sites ready, and first patient enrolled	
 	

AutoPrep	
 	

CellTracks	
 	

3

5	
 	

333,000
	

9b	
 	

5.2.12.2	
 	

"	
 	

Interim Patient Accrual Review	
 	

6/30/05	
 	

3/31/06	
 	

[**] of patients properly accrued and progress review/timeline approved by Steering Committee	
 	

AutoPrep	
 	

CellTracks	
 	

 	
 	

250,000
	

9c	
 	

5.2.12.3	
 	

"	
 	

Deliver Regulatory Submission to OCD	
 	

12/31/06	
 	

12/31/07	
 	

Steering Committee approves regulatory submission	
 	

AutoPrep	
 	

CellTracks	
 	

 	
 	

500,000
	

10a	
 	

5.2.13.1	
 	

Colorectal or Breast Cancer: Adjuvant Prognosis and Recurrence Monitoring	
 	

Initiate Clinical Study	
 	

4/30/04	
 	

1/31/05	
 	

Steering Committee approves readiness, protocol sent to FDA, sites ready, and first patient enrolled	
 	

AutoPrep	
 	

CellTracks	
 	

3

5	
 	

333,000
	

10b	
 	

5.2.13.2	
 	

"	
 	

Interim Patient Accrual Review	
 	

9/30/05	
 	

6/30/06	
 	

[**] of patients properly accrued and progress review/timeline approved by Steering Committee	
 	

AutoPrep	
 	

CellTracks	
 	

 	
 	

250,000

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

	10c	 	5.2.13.3	 	"	 	Deliver Regulatory Submission to OCD	 	12/31/05	 	12/31/07	 	Steering Committee approves regulatory submission for adjuvant prognosis	 	AutoPrep	 	CellTracks	 	 	 	500,000
	11	 	5.2.14	 	Tumor Cell Profiling	 	[**]	 	12/31/03	 	9/30/04	 	Steering Committee approves Prod Dev Process, [**] commercially available, [**] completes Production Readiness Review, and [**] has demonstrated proof of principle and acquired antibody	 	AutoPrep	 	CellTracks	 	 	 	200,000
	12	 	5.2.15	 	Large Volume Sample Processing	 	 	 	10/31/05	 	7/31/06	 	Development and Steering Committee approved clinical/regulatory strategy completed; commercial readiness with regulatory approval	 	AutoPrep	 	CellTracks	 	 	 	500,000

Notes related to Milestones in table: 

	1.
	The
following minimum requirements must be met:

	•
	FDA
regulatory approval received

	•
	Minimum
3 lots of materials manufactured under GMP compliance (or current FDA standard for lots and quality compliance)

	•
	Demonstrated
ability to produce the forecasted quantities of materials

	•
	Inventory
in place for Commercial Launch

	2.
	Five
Hundred Thousand Dollars (US$500,000) will be paid upon receipt of FDA approval for the Breast Cancer Therapy Monitoring submission based on the IMMC01 trial using
semi-automated sample processing (CellPrep) and CellSpotter. The remaining One Million Dollars (US$1,000,000) will be paid upon completion of the milestone as defined in the table. 

2a.
The parties agree that there shall be no completion date subject to adjustment under Section 5.4 for this milestone 5.2.6, and that in lieu thereof Immunicon's share of Net Sales of the
Cellular Analysis Product to which this milestone relates, under Section 6.2, shall be set at 30.5%. 

	3.
	A
minimum of [**] clinical sites will have achieved approval and sign-off from Principal Investigator and from IRB. Clinical sites will have been
trained, under contract, and materials will have been delivered.

	4.
	Exhibit Y
identifies the experiments planned to address the identified criteria. These experiments may be modified with agreement between OCD and Immunicon.

	5.
	In
addition to cell enumeration, blood will also be processed with [**] and [**] will be processed and stored for testing.

	6.
	This
table is a summary of milestone information from the Agreement. Any interpretation of the milestone provisions shall be governed by the terms set forth in the text of the
Agreement.

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

 
 

Exhibit Y: Requirements for the Large Volume Sample Processor to be used for the Prostate Cancer [**] Milestone(a)(b)    
    

	1.
	The
Large Volume Sample Processor (LVSP) must meet its functional requirements using whole blood collected in CellSave tubes.

	2.
	The
LVSP will process a large (up to [**] mLs) volume of whole blood and deliver a tumor cell enriched fraction into a standard AutoPrep sample tube, such that
the sample may then be placed on AutoPrep without further pre-processing.

	3.
	The
LVSP must demonstrate the number of recovered cells using the [**] mL blood volume reduction protocol is at least [**] the number
recovered when using [**] mL samples. This will be measured after LVSP processing, but before AutoPrep cell enrichment sample processing (AutoPrep input):

	•
	The
total number of leukocytes recovered from a [**] mL whole blood sample processed using the LVSP is at least [**] the
number of leukocytes recovered from [**] mLs of whole blood.

	4.
	Processing
of Tumor cell lines on the LVSP should not affect negatively their ability to be recovered by AutoPrep, or the accuracy of their reading on CellSpotter and/or CellTracks.
This will be measured after LVSP and AutoPrep / Cell enrichment sample processing (AutoPrep Output):

	•
	The
leukocyte carryover into a CellTracks chamber from LVSP processed samples should not exceed, on average, the leukocyte carryover of the sum of
[**] whole blood samples when processed on AutoPrep.

	•
	The
total number of spiked tumor cells recovered from a [**] mL whole blood sample processed using the LVSP is at least [**]
the number of tumor cells recovered from [**] of whole blood. Testing should be conducted at a tumor cell spike level of [**] mLs.

	5.
	The
Normal Reference Range should be less than or equal to [**] that of a single [**] mL tube. The functional sensitivity for tumor cell
detection per mL of sample (as determined by titrating spiked cells) must be [**] lower than that of a single [**] mL tube. For example, if the
functional sensitivity determined in a [**] mL sample is [**], then the functional sensitivity determined in a [**] mL sample
must be less than or equal to [**]. Working with the LVSPs New Product Proposal, or equivalent design control document, which incorporates the MECs, the Normal Reference Range
and the functional sensitivity shall be judged by the Steering Committee as to the LVSP's acceptability for its intended use.

	6.
	Demonstrate
that the LVSP processing, followed by AutoPrep sample enrichment is compatible with [**] analysis of the enriched cell population. The quality of
the [**] must be similar to that obtained from [**] mL samples. 

	(a)
	The
experiments used to demonstrate performance will be designed by Immunicon personnel, and performed according to written protocols. In advance of their execution, the Steering
Committee must agree that the design will yield results that adequately, and properly address the performance being tested.

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.

	(b)
	The
analysis platform for feasibility experiments will be either CellSpotter or CellTracks. If Cell Spotter is used for feasibility demonstration, then equivalence must be
demonstrated on CellTracks 

	 	 	Veridex, LLC
	

 	
 	

By:	
 	

/s/ ROY N. DAVIS
 Roy N. Davis

President

	ACCEPTED AND AGREED	 	 
	

IMMUNICON CORPORATION	
 	

 
	

By:	
 	

/s/ EDWARD L. ERICKSON
	
 	

 
	Name:	 	Edward L. Erickson
	 	 
	Title:	 	Chairman, President & CEO
	 	 
	Date:	 	11/13/03
	 	 

QuickLinks

Exhibit 10.29

Exhibit X: Revised Milestone Table(6)

Exhibit Y: Requirements for the Large Volume Sample Processor to be used for the Prostate Cancer [**] Milestone(a)(b)QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.46    
    

 
 

IMMUNICON CORPORATION
  2004 EMPLOYEE STOCK PURCHASE PLAN    
    

 

I.     PURPOSE OF THE PLAN  

        The Plan (as defined in Article II) is intended to promote the interests of the Company (as defined in Article II) by providing eligible employees
of a Participating Employer (as defined in Article II) with the opportunity to acquire a proprietary interest in the Company through participation in a payroll deduction-based employee stock purchase
plan designed to qualify under section 423 of the Code. The Plan is not intended and shall not be construed as constituting an "employee benefit plan," within the meaning of section 3(3)
of the Employee Retirement Income Security Act of 1974, as amended. 

II.    DEFINITIONS  

        A. "Board" shall mean the Company's Board of Directors. 

        B.
"Change in Control" shall mean a change in ownership of the Company pursuant to any of the following transactions: 

	(i)
	Any
"person" (as such term is used in sections 13(d) and 14(d) of the Exchange Act) becomes a "beneficial owner" (as defined in Rule 13d-3 under the
Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities of the Company; provided that a Change in Control
shall not be deemed to occur as a result of the initial public offering of the Common Stock and a Change in Control shall not be deemed to occur as a result of a transaction in which the Company
becomes a subsidiary of another corporation and in which the stockholders of the Company, immediately prior to the transaction, will beneficially own, immediately after the transaction, shares
entitling such stockholders to more than 50% of all votes to which all stockholders of the parent corporation would be entitled in the election of directors (without consideration of the rights of any
class of stock to elect directors by a separate class vote);

	(ii)
	The
consummation of (A) a merger or consolidation of the Company with another corporation where the stockholders of the Company, immediately prior to the merger
or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the surviving
corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote), (B) a sale or other
disposition of all or substantially all of the assets of the Company, or (C) a liquidation or dissolution of the Company; or

	(iii)
	After
the date on which this Plan is approved by the stockholders of the Company, directors are elected such that a majority of the members of the Board shall have
been members of the Board for less than two years, unless the election or nomination for election of each new director who was not a director at the beginning of such two-year period was
approved by a vote of at least two-thirds of the directors then still in office who were directors at the beginning of such period. 

        C.
"Code" shall mean the Internal Revenue Code of 1986, as amended. 

        D.
"Common Stock" shall mean the common stock of the Company. 

        E.
"Company Affiliate" shall mean any parent or subsidiary corporation of the Company (as determined in accordance with section 424
of the Code), whether now existing or subsequently established. 

1

 

        F.
"Company" shall mean Immunicon Corporation, a Delaware corporation, and any corporate successor to all or substantially all of the
assets or voting stock of Immunicon Corporation that shall by appropriate action adopt the Plan. 

        G.
"Compensation" shall mean (i) the regular base salary paid to a Participant by one or more Participating Employers during the
Participant's period of participation in one or more offering periods under the Plan plus (ii) all overtime payments, bonuses, commissions, profit-sharing distributions or other
incentive-type payments received during such period. Such Compensation shall be calculated before deduction of (A) any income or employment tax withholdings or (B) any
contributions made by the Participant to any section 401(k) of the Code salary deferral plan or any section 125 of the Code cafeteria benefit program now or hereafter established by the
Company or any Company Affiliate. However, Compensation shall not include any contributions made by the Company or any Company Affiliate on the Participant's behalf to any employee benefit or welfare
plan now or hereafter established (other than section 401(k) of the Code or section 125 of the Code contributions deducted from such Compensation). 

        H.
"Effective Time" shall mean the time at which the Underwriting Agreement is executed and the Common Stock is priced for the initial
public offering of such Common Stock. Any Company Affiliate that becomes a Participating Employer after such Effective Time shall designate an effective date with respect to its employee-Participants. 

        I.
"Eligible Employee" shall mean any person who is employed by a Participating Employer on a basis under which he or she is regularly
expected to render more than twenty (20) hours of service per week for more than five (5) months per calendar year for earnings considered wages under section 3401(a) of the Code. 

        J.
"Exchange Act" shall mean the Securities Exchange Act of 1934, as amended. 

        K.
"Fair Market Value" per share of Common Stock on any relevant date shall be determined in accordance with the following provisions: 

	(i)
	If
the Common Stock is at the time traded on the Nasdaq National Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the
date in question, as such price is reported by the National Association of Securities Dealers on the Nasdaq National Market and published in The Wall Street Journal. If there is no closing selling
price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

	(ii)
	If
the Common Stock is at the time listed on any Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in
question on the Stock Exchange determined by the Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such
exchange and published in The Wall Street Journal. If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on
the last preceding date for which such quotation exists.

	(iii)
	For
purposes of the initial offering period that begins at the Effective Time, the Fair Market Value shall be deemed to be equal to the price per share at which the
Common Stock is sold in the initial public offering pursuant to the Underwriting Agreement. 

        L.
"1933 Act" shall mean the Securities Act of 1933, as amended. 

        M.
"Participant" shall mean any Eligible Employee of a Participating Employer who is actively participating in the Plan. 

2

 

        N.
"Participating Employer" shall mean the Company and such Company Affiliate(s) as may be authorized from time to time by the Board to
extend the benefits of the Plan to their Eligible Employees. 

        O.
"Plan" shall mean the Immunicon Corporation 2004 Employee Stock Purchase Plan, as set forth in this document. 

        P.
"Plan Administrator" shall mean the committee of two (2) or more Board members appointed by the Board to administer the Plan or
such other committee appointed by the Board to administer the Plan. 

        Q.
"Purchase Date" shall mean the last business day of each Purchase Interval. The initial Purchase Date shall be the last business day of
the first Purchase Interval. 

        R.
"Purchase Interval" shall mean each successive six (6)-month period within a particular offering period at the end of which there shall
be purchased shares of Common Stock on behalf of each Participant. 

        S.
"Stock Exchange" shall mean either the American Stock Exchange or the New York Stock Exchange. 

        T.
"Underwriting Agreement" shall mean the agreement between the Company and the underwriter or underwriters managing the initial public
offering of the Common Stock. 

III.  ADMINISTRATION OF THE PLAN  

        The Plan Administrator shall have full discretionary authority to interpret and construe any provision of the Plan and to adopt such rules and regulations for
administering the Plan as it may deem necessary in order to comply with the requirements of section 423 of the Code. Decisions of the Plan Administrator shall be final and binding on all
parties having an interest in the Plan. As a condition of participating in the Plan, all Participants must acknowledge, in writing or by completing the enrollment forms to participate in the Plan,
that all decisions and determinations of the Plan Administrator shall be final and binding on the Participant, his or her beneficiaries and any other person having or claiming an interest under the
Plan on behalf of the Participant. 

IV.    STOCK SUBJECT TO PLAN  

        A. The stock purchasable under the Plan shall be shares of authorized but unissued or reacquired Common Stock, including shares of Common Stock purchased on the
open market. The number of shares of Common Stock initially reserved for issuance over the term of the Plan shall be limited to 200,000 shares. 

        B.
Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the
outstanding Common Stock as a class without the Company's receipt of consideration, appropriate adjustments shall be made to (i) the maximum number and class of securities issuable under the
Plan, (ii) the maximum number and class of securities purchasable per Participant on any one Purchase Date, (iii) the maximum number and class of securities purchasable in total by all
Participants on any one Purchase Date, and (iv) the number and class of securities and the price per share in effect under each outstanding purchase right, in order to prevent the dilution or
enlargement of benefits thereunder. 

V.     OFFERING PERIODS  

        A. Shares of Common Stock shall be offered for purchase under the Plan through a series of overlapping offering periods until such time as (i) the maximum
number of shares of Common Stock 

3

 

available
for issuance under the Plan shall have been purchased or (ii) the Plan shall have been sooner terminated. 

        B.
Each offering period shall be of such duration (not to exceed twenty-four (24) months) as determined by the Plan Administrator prior to the start date of such
offering period. However, the initial offering period shall commence at the Effective Time and terminate on the last business day of the following twenty-four (24) month period. 

        C.
Each offering period shall consist of a series of one or more successive Purchase Intervals. The first Purchase Interval in effect under the initial offering period shall commence at
the Effective Time and terminate on the last business day of the following six (6) month period. 

        D.
Should the Fair Market Value per share of Common Stock on any Purchase Date within a particular offering period be less than the Fair Market Value per share of Common Stock on the
start date of that offering period, then the individuals participating in such offering period shall, immediately after the purchase of shares of Common Stock on their behalf on such Purchase Date, be
transferred from that offering period and automatically enrolled in the next offering period commencing after such Purchase Date. 

VI.   ELIGIBILITY  

        A. Each individual who is an Eligible Employee on the start date of any offering period under the Plan may enter that offering period on such start date. However,
an Eligible Employee may participate in only one offering period at a time. For the initial offering period commencing at the Effective Time, each individual who is an Eligible Employee at that time
shall automatically be enrolled as a Participant with a contribution rate equal to ten percent (10%) of his or her Compensation. 

        B.
Except as otherwise provided in Sections V.D and VI.A. above, an Eligible Employee must, in order to participate in the Plan for a particular offering period, complete the enrollment
forms prescribed by
the Plan Administrator (including a stock purchase agreement and a payroll deduction authorization) and file such forms with the Plan Administrator (or its designate) at such time on or before the
start date of that offering period, as determined by the Plan Administrator. 

VII. PAYROLL DEDUCTIONS  

        A. The payroll deduction authorized by the Participant for purposes of acquiring shares of Common Stock during an offering period may be any multiple of one
percent (1%) of the Compensation paid to the Participant during each Purchase Interval within that offering period, up to a maximum of ten percent (10%). The deduction rate so authorized shall
continue in effect throughout the offering period, except to the extent such rate is changed in accordance with the following guidelines: 

	(i)
	The
Participant may, at any time during the offering period, reduce his or her rate of payroll deduction (or, to the extent applicable, the percentage of Compensation to
serve as his or her lump sum contribution for the initial Purchase Interval of the first offering period) to become effective as soon as possible after filing the appropriate form with the Plan
Administrator. The Participant may not, however, effect more than one (1) such reduction per Purchase Interval.

	(ii)
	The
Participant may, prior to the commencement of any new Purchase Interval within the offering period, increase the rate of his or her payroll deduction by filing the
appropriate form with the Plan Administrator. The new rate (which may not exceed the ten percent (10%) maximum) shall become effective on the start date of the first Purchase Interval following the
filing of such form. 

4

 

        B.
Payroll deductions shall begin on the first pay day administratively feasible following the start date of the offering period and shall (unless sooner terminated by the Participant)
continue through the pay day ending with or immediately prior to the last day of that offering period. The amounts so collected shall be credited to the Participant's book account under the Plan, but
no interest shall be paid on the balance from time to time outstanding in such account. The amounts collected from the Participant shall not be required to be held in any segregated account or trust
fund and may be commingled with the general assets of the Company and used for general corporate purposes. 

        C.
For the initial Purchase Interval of the first offering period under the Plan, no payroll deductions shall be required of the Participant until such time as the Participant
affirmatively elects to commence
such payroll deductions following his or her receipt of the 1933 Act prospectus for the Plan. In the absence of such payroll deductions, if the Participant elects to have shares of Common Stock
purchased on his or her behalf on the Purchase Date for that initial Purchase Interval, the Participant will be required to contribute the applicable percentage of his or her Compensation to the Plan
in a lump sum payment immediately prior to the close of that Purchase Interval. 

        D.
Payroll deductions shall automatically cease upon the termination of the Participant's purchase right in accordance with the provisions of the Plan. 

        E.
The Participant's acquisition of Common Stock under the Plan on any Purchase Date shall neither limit nor require the Participant's acquisition of Common Stock on any subsequent
Purchase Date, whether within the same or a different offering period. 

VIII.     PURCHASE RIGHTS  

        A. Grant of Purchase Rights. A Participant shall be granted a separate purchase right for each offering period in
which he or she is enrolled. The purchase right shall be granted on the start date of the offering period and shall provide the Participant with the right to purchase shares of Common Stock, in a
series of successive installments during that offering period, upon the terms set forth below. The Participant shall execute a stock purchase agreement embodying such terms and such other provisions
(not inconsistent with the Plan) as the Plan Administrator may deem advisable. 

        Under
no circumstances shall purchase rights be granted under the Plan to any Eligible Employee if such individual would, immediately after the grant, own (within the meaning of
section 424(d) of the Code) or hold outstanding options or other rights to purchase, stock possessing five percent (5%) or more of the total combined voting power or value of all classes of
stock of the Company or any Company Affiliate. 

        B.
Exercise of the Purchase Right. Each purchase right shall be automatically exercised in installments on each successive Purchase Date
within the offering period, and shares of Common Stock shall accordingly be purchased on behalf of each Participant on each such Purchase Date. The purchase shall be effected by applying the
Participant's payroll deductions (or, to the extent applicable, his or her lump sum contribution) for the Purchase Interval ending on such Purchase Date to the purchase of whole shares of Common Stock
at the purchase price in effect for the Participant for that Purchase Date. 

        C.
Purchase Price. The purchase price per share at which Common Stock will be purchased on the Participant's behalf on each Purchase Date
within the particular offering period in which he or she is enrolled shall be equal to, unless the Plan Administrator determines otherwise prior to the beginning of
the particular offering period, eighty-five percent (85%) of the lower of (i) the Fair Market Value per share of Common Stock on the start date of that offering period or
(ii) the Fair Market Value per share of Common Stock on that Purchase Date. 

        D.  Number of Purchasable Shares. The number of shares of Common Stock purchasable by a Participant on each Purchase Date during the
particular offering period in which he or she is enrolled 

5

 

shall
be the number of whole shares obtained by dividing the amount collected from the Participant through payroll deductions during the Purchase Interval ending with that Purchase Date (or, to the
extent applicable, his or her lump sum contribution for that Purchase Interval) by the purchase price in effect for the Participant for that Purchase Date. However, the maximum number of shares of
Common Stock purchasable per Participant on any one Purchase Date shall not exceed 5,000 shares, subject to periodic adjustments in the event of certain changes in the Company's capitalization. In
addition, the maximum number of shares of Common Stock purchasable in total by all Participants in the Plan on any one Purchase Date shall not exceed 100,000 shares, subject to periodic adjustments in
the event of certain changes in the Company's capitalization. However, the Plan Administrator shall have the discretionary authority, exercisable prior to the start of any offering period under the
Plan, to increase or decrease the limitations to be in effect for the number of shares purchasable per Participant and in total by all Participants enrolled in that particular offering period on each
Purchase Date which occurs during that offering period. 

        E.  Excess Payroll Deductions. Any payroll deductions not applied to the purchase of shares of Common Stock on any Purchase Date because
they are not sufficient to purchase a whole share of Common Stock shall be held for the purchase of Common Stock on the next Purchase Date. However, any payroll deductions not applied to the purchase
of Common Stock by reason of the limitation on the maximum number of shares purchasable per Participant or in total by all Participants on the Purchase Date shall be promptly refunded. 

        F.
Suspension of Payroll Deductions. In the event that a Participant is, by reason of the accrual limitations in Article IX,
precluded from purchasing additional shares of Common Stock on one or more Purchase Dates during the offering period in which he or she is enrolled, then no further payroll deductions shall be
collected from such Participant with respect to those Purchase Dates. The suspension of such deductions shall not terminate the Participant's purchase right for the offering period in which he or she
is enrolled, and payroll deductions shall automatically resume on behalf of such Participant once he or she is again able to purchase shares during that offering period in compliance with the accrual
limitations of Article IX. 

        G.
Withdrawal from Offering Period. The following provisions shall govern the Participant's withdrawal from an offering period: 

	(i)
	A
Participant may withdraw from the offering period in which he or she is enrolled at any time prior to the next scheduled Purchase Date by filing the appropriate form
with the Plan Administrator (or its designate), and no further payroll deductions shall be collected from the Participant with respect to that offering period. Any payroll deductions collected during
the Purchase Interval in which such withdrawal occurs shall, at the Participant's election, be immediately refunded or held for the purchase of shares on the next Purchase Date. If no such election is
made at the time of such withdrawal, then the payroll deductions collected from the Participant during the Purchase Interval in which such withdrawal occurs shall be refunded as soon as possible.

	(ii)
	The
Participant's withdrawal from a particular offering period shall be irrevocable, and the Participant may not subsequently rejoin that offering period at a later
date. In order to resume participation in any subsequent offering period, such individual must re-enroll in the Plan (by making a timely filing of the prescribed enrollment forms) on or
before the start date of that offering period. 

        H.
Termination of Purchase Right. Should the Participant cease to remain an Eligible Employee for any reason (including death, disability
or change in status) while his or her purchase right remains outstanding, then that purchase right shall immediately terminate, and all of the Participant's payroll deductions for the Purchase
Interval in which the purchase right so terminates shall be immediately refunded. 

6

 

        I.
Change in Control. Each outstanding purchase right shall automatically be exercised, immediately prior to the effective date of any
Change in Control, by applying the payroll deductions of each Participant for the Purchase Interval in which such Change in Control occurs to the purchase of whole shares of Common Stock at a purchase
price per share equal to, unless the Plan Administrator determines otherwise prior to the beginning of the particular offering period, eighty-five percent (85%) of the lower of
(i) the Fair Market Value per share of Common Stock on the start date of the offering period in which such individual is enrolled at the time of such Change in Control or (ii) the Fair
Market Value per share of Common Stock immediately prior to the effective date of such Change in Control. However, the applicable limitation on the number of shares of Common Stock purchasable per
Participant shall continue to apply to any such purchase, but not the limitation applicable to the maximum number of shares of Common Stock purchasable in total by all Participants on any one Purchase
Date. 

        The
Company shall, if reasonably practicable, provide at least ten (10) days' prior written notice of the occurrence of any Change in Control, and Participants shall, following
the receipt of such notice, have the right to terminate their outstanding purchase rights prior to the effective date of the Change in Control. 

        J.
Proration of Purchase Rights. Should the total number of shares of Common Stock to be purchased pursuant to outstanding purchase rights
on any particular date exceed the number of shares then available for issuance under the Plan, the Plan Administrator shall make a pro-rata allocation of the available shares on a uniform
and nondiscriminatory basis, and the payroll deductions of each Participant, to the extent in excess of the aggregate purchase price payable for the Common Stock pro-rated to such
individual, shall be refunded. 

        K.
Assignability. The purchase right shall be exercisable only by the Participant and shall not be assignable or transferable by the
Participant. 

        L.
Stockholder Rights. A Participant shall have no stockholder rights with respect to the shares subject to his or her outstanding
purchase right until the shares are purchased on the Participant's behalf in accordance with the provisions of the Plan and the Participant has become a holder of record of the purchased shares. 

IX.   ACCRUAL LIMITATIONS  

        A. No Participant shall be entitled to accrue rights to acquire Common Stock pursuant to any purchase right outstanding under this Plan if and to the extent such
accrual, when aggregated with (i) rights to purchase Common Stock accrued under any other purchase right granted under this Plan and (ii) similar rights accrued under other employee
stock purchase plans (within the meaning of section 423 of the Code)) of the Company or any Company Affiliate, would otherwise permit such Participant to purchase more than $25,000 worth of
stock of the Company or any Company Affiliate (determined on the basis of the Fair Market Value per share on the date or dates such rights are granted) for each calendar year such rights are at any
time outstanding. 

        B.
For purposes of applying such accrual limitations to the purchase rights granted under the Plan, the following provisions shall be in effect: 

	(i)
	The
right to acquire Common Stock under each outstanding purchase right shall accrue in a series of installments on each successive Purchase Date during the offering
period in which such right remains outstanding.

	(ii)
	No
right to acquire Common Stock under any outstanding purchase right shall accrue to the extent the Participant has already accrued in the same calendar year the right
to acquire Common Stock under one or more other purchase rights at a rate equal to Twenty-Five Thousand Dollars ($25,000.00) worth of Common Stock (determined on the 

7

 

basis
of the Fair Market Value per share on the date or dates of grant) for each calendar year such rights were at any time outstanding. 

        C.
If by reason of such accrual limitations, any purchase right of a Participant does not accrue for a particular Purchase Interval, then the payroll deductions that the Participant made
during that Purchase Interval with respect to such purchase right shall be promptly refunded. 

        D.
In the event there is any conflict between the provisions of this Article and one or more provisions of the Plan or any instrument issued thereunder, the provisions of this Article
shall be controlling. 

X.    EFFECTIVE TIME AND TERM OF THE PLAN  

        A. The Plan was adopted by the Board on January 23, 2004, and shall become effective at the Effective Time, provided no purchase rights granted under the
Plan shall be exercised, and no shares of Common Stock shall be issued hereunder, until (i) the Plan shall have been approved by the stockholders of the Company and (ii) the Company
shall have complied with all applicable requirements of the 1933 Act (including the registration of the shares of Common Stock issuable under the Plan on a Form S-8 registration
statement filed with the Securities and Exchange Commission), all applicable listing requirements of any stock exchange (or the Nasdaq National Market, if applicable) on which the Common Stock is
listed for trading and all other applicable requirements established by law or regulation. In the event such stockholder approval is not obtained, or such compliance is not effected, within twelve
(12) months after the date on which the Plan is adopted by the Board, the Plan shall terminate and have no further force or effect, and all sums collected from Participants during the initial
offering period hereunder shall be refunded. 

        B.
Unless sooner terminated by the Board, the Plan shall terminate upon the earliest of (i) the last business day in the ten (10) year period following the Effective Time,
(ii) the date on which all shares available for issuance under the Plan shall have been sold pursuant to purchase rights exercised under the Plan or (iii) the date on which all purchase
rights are exercised in connection with a Change in Control. No further purchase rights shall be granted or exercised, and no further payroll deductions shall be collected, under the Plan following
such termination. 

XI.   AMENDMENT OF THE PLAN  

        A. The Board may alter, amend, suspend or terminate the Plan at any time to become effective immediately following the close of any Purchase Interval. However,
the Plan may be amended or terminated immediately upon Board action, if and to the extent necessary to assure that the Company will not recognize, for financial reporting purposes, any compensation
expense in connection with the shares of Common Stock offered for purchase under the Plan, should the financial accounting rules applicable to the Plan at the Effective Time be subsequently revised so
as to require the Company to recognize compensation expense in the absence of such amendment or termination. 

        B.
In no event may the Board effect any of the following amendments or revisions to the Plan without the approval of the Company's stockholders: (i) increase the number of shares
of Common Stock issuable under the Plan, except for permissible adjustments in the event of certain changes in the Company's capitalization, (ii) alter the purchase price formula so as to
reduce the purchase price payable for the shares of Common Stock purchasable under the Plan or (iii) modify the eligibility requirements for participation in the Plan. 

8

 

XII. GENERAL PROVISIONS  

        A. All costs and expenses incurred in the administration of the Plan shall be paid by the Company; however, each Plan Participant shall bear all costs and
expenses incurred by such individual in the sale or other disposition of any shares purchased under the Plan. 

        B.
Nothing in the Plan shall confer upon the Participant any right to continue in the employ of the Company or any Company Affiliate for any period of specific duration or interfere with
or otherwise restrict in any way the rights of the Company (or any Company Affiliate employing such person) or of the Participant, which rights are hereby expressly reserved by each, to terminate such
person's employment at any time for any reason, with or without cause. 

        The
provisions of the Plan shall be governed by the laws of the Commonwealth of Pennsylvania, without resort to that Commonwealth's conflict-of-laws rules. 

9

QuickLinks

Exhibit 10.46

IMMUNICON CORPORATION 2004 EMPLOYEE STOCK PURCHASE PLAN

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]